A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Conditions:   Differentiated Thyroid Cancer (DTC);   Poorly Differentiated Thyroid Cancer
Intervention:   Drug: Cabozantinib
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified April 2016

from #ENT via xlomafota13 on Inoreader http://ift.tt/1ROy6Tm
via IFTTT